- Report
- August 2025
- 190 Pages
Global
From €3151EUR$3,545USD£2,735GBP
€3501EUR$3,939USD£3,039GBP
- Report
- August 2025
- 185 Pages
Global
From €3151EUR$3,545USD£2,735GBP
€3501EUR$3,939USD£3,039GBP
- Report
- August 2025
- 193 Pages
Global
From €3151EUR$3,545USD£2,735GBP
€3501EUR$3,939USD£3,039GBP
- Report
- August 2025
- 182 Pages
Global
From €3151EUR$3,545USD£2,735GBP
€3501EUR$3,939USD£3,039GBP
- Report
- August 2025
- 199 Pages
Global
From €3151EUR$3,545USD£2,735GBP
€3501EUR$3,939USD£3,039GBP
- Report
- August 2025
- 196 Pages
Global
From €3151EUR$3,545USD£2,735GBP
€3501EUR$3,939USD£3,039GBP
- Report
- October 2025
- 192 Pages
Global
From €3151EUR$3,545USD£2,735GBP
€3501EUR$3,939USD£3,039GBP
- Report
- August 2025
- 191 Pages
Global
From €3151EUR$3,545USD£2,735GBP
€3501EUR$3,939USD£3,039GBP
- Report
- October 2025
- 196 Pages
Global
From €3151EUR$3,545USD£2,735GBP
€3501EUR$3,939USD£3,039GBP
- Report
- October 2025
- 184 Pages
Global
From €3151EUR$3,545USD£2,735GBP
€3501EUR$3,939USD£3,039GBP
- Report
- October 2025
- 182 Pages
Global
From €3151EUR$3,545USD£2,735GBP
€3501EUR$3,939USD£3,039GBP
- Report
- October 2025
- 198 Pages
Global
From €3151EUR$3,545USD£2,735GBP
€3501EUR$3,939USD£3,039GBP
- Report
- October 2025
- 198 Pages
Global
From €3151EUR$3,545USD£2,735GBP
€3501EUR$3,939USD£3,039GBP
- Report
- October 2025
- 193 Pages
Global
From €3151EUR$3,545USD£2,735GBP
€3501EUR$3,939USD£3,039GBP
- Report
- October 2025
- 182 Pages
Global
From €3151EUR$3,545USD£2,735GBP
€3501EUR$3,939USD£3,039GBP
- Report
- October 2025
- 180 Pages
Global
From €3151EUR$3,545USD£2,735GBP
€3501EUR$3,939USD£3,039GBP
- Report
- October 2025
- 199 Pages
Global
From €3151EUR$3,545USD£2,735GBP
€3501EUR$3,939USD£3,039GBP
- Report
- October 2025
- 198 Pages
Global
From €3151EUR$3,545USD£2,735GBP
€3501EUR$3,939USD£3,039GBP
- Report
- October 2025
- 189 Pages
Global
From €3151EUR$3,545USD£2,735GBP
€3501EUR$3,939USD£3,039GBP
- Report
- October 2025
- 184 Pages
Global
From €3151EUR$3,545USD£2,735GBP
€3501EUR$3,939USD£3,039GBP

Single Use Bioreactors (SUBs) are bioreactors that are designed for a single use and then disposed of. They are used in biotechnology for the production of biopharmaceuticals, such as vaccines, monoclonal antibodies, and recombinant proteins. SUBs are typically made of plastic and are pre-sterilized, eliminating the need for cleaning and sterilization between batches. This makes them ideal for rapid scale-up and production of biopharmaceuticals. SUBs also offer advantages such as reduced risk of contamination, improved process control, and reduced capital costs.
The SUB market is growing rapidly due to the increasing demand for biopharmaceuticals and the need for rapid scale-up and production. SUBs are becoming increasingly popular in the biotechnology industry due to their cost-effectiveness and convenience.
Some companies in the SUB market include Sartorius, Thermo Fisher Scientific, Merck KGaA, GE Healthcare, and Pall Corporation. Show Less Read more